In recent years, dysregulated TFIIH complex has been reported as a master regulatory machine in cancer progression of solid and hematologic malignancies [15, 49], and the main subunit CDK7 is recognized as a druggable target in cancer treatment. The gene discussed is ERCC3; the disease is hematologic disorder.